| Literature DB >> 31623426 |
Yunsu Choi1,2, Bo Youl Choi1,2, Soo Min Kim2,3, Sang Il Kim4, June Kim5, Jun Young Choi5, Shin-Woo Kim6, Joon Young Song7, Youn Jeong Kim4, Dae Won Park8, Hyo Youl Kim9, Hee-Jung Choi10, Mee-Kyung Kee11, Young Hyun Shin11, Myeongsu Yoo11.
Abstract
OBJECTIVES: To manage evidence-based diseases, it is important to identify the characteristics of patients in each country.Entities:
Keywords: AIDS-related opportunistic infections; Antiretroviral therapy highly active; Communicable diseases; HIV
Mesh:
Year: 2019 PMID: 31623426 PMCID: PMC6815876 DOI: 10.4178/epih.e2019037
Source DB: PubMed Journal: Epidemiol Health ISSN: 2092-7193
Figure 1.Annual new HIV infections (A: new infections in Korea1 ; B: new infections in Korea HIV/AIDS Cohort Study) by age. HIV, human immunodeficiency virus. 1 From Korea Centers for Disease Control. Korea notification of HIV/AIDS in 2017 [Internet] [15].
General characteristics of research participants
| Variables | n (%) |
|---|---|
| Gender | |
| Men | 1,345 (93.3) |
| Women | 97 (6.7) |
| Marital status at HIV diagnosis | |
| Single | 770 (53.4) |
| Married/living together | 364 (25.2) |
| Separated/divorced/widowed | 125 (8.7) |
| Others | 141 (9.8) |
| Missing | 42 (2.9) |
| Marital status at baseline | |
| Single | 754 (52.3) |
| Married/living together | 353 (24.5) |
| Separated/divorced/widowed | 153 (10.6) |
| Others | 140 (9.7) |
| Missing | 42 (2.9) |
| Acute symptom of HIV | |
| Yes | 805 (55.8) |
| No | 578 (40.1) |
| Unknown | 43 (3.0) |
| Missing | 16 (1.1) |
| Transmission mode | |
| Homosexual | 493 (34.2) |
| Bisexual | 378 (26.2) |
| Heterosexual | 491 (34.0) |
| Transfusion/blood products | 5 (0.3) |
| Injected drug use | 1 (0.1) |
| Vertical transmission | 0 (0.0) |
| Others | 5 (0.3) |
| Unknown/no answer | 70 (4.9) |
| Transmission place | |
| Korea | 889 (61.6) |
| Abroad | 161 (11.2) |
| Unknown | 392 (27.2) |
HIV, human immunodeficiency virus.
Figure 2.Depression and anxiety status of patients with HIV infection. Values are presented as number. HIV, human immunodeficiency virus; BDI, Beck’s Depression Inventory; STAI-X-1, State-Trait Anxiety Inventory. 1 Minimal: <10; mild: 10-15; moderate: 16-23; severe: >-24. 2 Minimal: <52; mild: 52-56; moderate: 57-61; severe: >-62.
Characteristics of antiretroviral therapy (ART)
| Characteristics | n (%) or median [IQR] |
|---|---|
| ART | |
| Yes | 1,285 (89.1) |
| No | 157 (10.9) |
| Initial ART regimen | |
| 2 NRTI+PI | 716 (55.7) |
| 2 NRTI+NNRTI | 372 (28.9) |
| 2 NRTI+INI | 138 (10.7) |
| Others[ | 57 (4.4) |
| Unknown | 2 (0.2) |
| Frequency of skipping antiretroviral drugs (multiple responses) | |
| Never once | 2,225 (56.6) |
| Once a month | 532 (13.5) |
| Once a week | 217 (5.5) |
| Once in 2 weeks | 208 (5.3) |
| More than twice a week | 118 (3.0) |
| Daily | 33 (0.8) |
| Others | 269 (6.8) |
| Missing | 328 (8.4) |
| Cause of skipping ART (multiple responses) | |
| Side effects of antiretroviral drugs | 14,318 (91.1) |
| Fear of exposure of diagnosis | 834 (5.3) |
| Low socioeconomic status | 71 (0.4) |
| Excessive number of pills | 45 (0.3) |
| Not eating a meal | 58 (0.3) |
| Simply forgot | 15 (0.1) |
| Misinformation about ART | 11 (0.1) |
| Others | 9 (0.1) |
| Missing | 359 (2.3) |
| CD4 T cell count (within 3 mo) | |
| At HIV diagnosis | 852 (59.0)/229.5 [85.5-360.5] |
| At the start of initial ART | 563 (43.8)/179 [60-279] |
| At finish of initial ART | 559 (45.0)/331 [185-465] |
| HIV RNA (within 3 mo) | |
| At HIV diagnosis | 800 (55.4)/63,207.5 [14,731.5-224,834.0] |
| At the start of initial ART | 524 (40.8)/77,100 [20,200-240,000] |
| At finish of initial ART | 539 (41.9)/41 [20-342] |
IQR, interquartile range; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; INI, integrase inhibitor; HIV, human immunodeficiency virus.
Others: NRTI, 2 NRTI, NRTI+PI, PI, NRTI+NNRTI, 3 NRTI+PI, NRTI+INI+PI, NRTI+NNRTI+PI, 3 NRTI, INI, NNRTI+PI.
Characteristics of AIDS-related diseases (including opportunistic infections)
| Characteristics | n (%) (n=1,442)[ |
|---|---|
| AIDS-related/defining diseases[ | |
| Tuberculosis (mycobacterium, non-mycobacterium) | 240 (16.6) |
| Syphilis | 135 (9.4) |
| Candidiasis, oropharyngeal (thrush) | 65 (4.5) |
| Pneumocystis carinii pneumonia | 53 (3.7) |
| Cytomegalovirus disease | 39 (2.7) |
| Herpes zoster | 28 (1.9) |
| Candidiasis, esophageal | 22 (1.5) |
| Herpes simplex | 20 (1.4) |
| Herpes simplex virus: bronchitis, pneumonia, or esophagitis | 20 (1.4) |
| Peripheral neuropathy | 9 (0.6) |
| HIV-related encephalopathy | 7 (0.5) |
| Wasting syndrome due to HIV | 6 (0.4) |
| Kaposi’s sarcoma | 5 (0.3) |
| Idiopathic thrombocytopenic purpura | 4 (0.3) |
| Burkitt’s lymphoma | 4 (0.3) |
| Pneumonia (recurrent) | 4 (0.3) |
| Candidiasis, vulvovaginal | 3 (0.2) |
| Cryptococcosis, extrapulmonary | 2 (0.1) |
| Cryptosporidiosis, chronic intestinal (>1 mo) | 2 (0.1) |
| Immunoblastic lymphoma | 2 (0.1) |
| Progressive multifocal leukoencephalopathy | 1 (0.1) |
| Toxoplasmosis of brain | 1 (0.1) |
| Cervical dysplasia (moderate or severe) | 1 (0.1) |
| Opportunistic infection[ | |
| Pneumocystis carinii pneumonia | 386 (26.7) |
| Candida | 155 (10.7) |
| Cytomegalovirus | 76 (5.3) |
| Cryptococcus neoformans | 8 (0.6) |
| Toxoplasma | 4 (0.3) |
| Salmonella | 2 (0.1) |
AIDS, acquired immune deficiency syndrome; HIV, human immunodeficiency virus.
Total prevalence rate.
Diagnosis since a year before HIV infection diagnosis to survey date.
A lifelong diagnosis experience regardless of the time of HIV diagnosis; No frequency of occurrence of bacillary angiomatosis, listeriosis, pelvic inflammatory disease, candidiasis of bronchi, trachea, or lungs, coccidiodomycosis, disseminated or extrapulmonary, isosporiasis, chronic intestinal (>1 month duration), herpes simplex virus with chronic ulcer(s) (>1 month duration), histoplasmosis, disseminated or extrapulmonary, salmonella septicemia (recurrent), cervical cancer (invasive), primary lymphoma of the brain.
Figure 3.Prevalence of non-AIDS-related diseases. AIDS, acquired immune deficiency syndrome.
Characteristics of termination survey
| Variables | n (%) |
|---|---|
| Termination rate | 509 (35.3) |
| Cause of termination | |
| Loss to follow up (2 yr) | 152 (29.9) |
| Withdraw consent | 95 (18.7) |
| Death | 84 (16.5) |
| Withdrawal of the hospital’s research | 70 (13.8) |
| Changing hospital | 52 (10.2) |
| Immigration | 1 (0.2) |
| Others | 55 (10.8) |
| Cause of death | |
| AIDS-related death | 15 (17.9) |
| Non-AIDS-related death | 7 (8.3) |
| Unknown/missing | 62 (73.8) |
AIDS, acquired immune deficiency syndrome.